
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is expected to continue to outperform in the market, with its current growth drivers and potential future high-performing assets, such as its recently acquired Apogee pipeline, contributing to its strong financials and stable market position. The company's strong exposure to immunology and oncology, along with its diversification into other therapeutic areas through recent acquisitions, further strengthens its profitability and resilience in the long term. With its solid track record of cash generation, dividend payout, and commitment to sustainability, AbbVie presents a compelling investment opportunity in the pharmaceutical sector.
Bears say
AbbVie is facing headwinds in key segments such as immunology, oncology, and aesthetics, with numerous competitive threats and pricing pressures. The recent acquisitions of Cerevel and ImmunoGen may not be enough to offset these challenges, and there is a risk of surprise negative trial results for their pipeline assets. Additionally, macroeconomic conditions and a potential rotation away from defensive stocks could also impact the company's performance.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares